Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases
暂无分享,去创建一个
L. León | L. Abasolo | L. Rodríguez-Rodríguez | J. Jover | B. Fernández-Gutiérrez | A. Mucientes | D. Freites Nuñez | A. Madrid García | J. I. Colomer | J. Font Urgelles
[1] L. Trupin,et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2020, Annals of the Rheumatic Diseases.
[2] A. Neimann,et al. Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York , 2020, The New England journal of medicine.
[3] Hangyuan Guo,et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis , 2020, Journal of Infection.
[4] P. Elkington,et al. Personal respirators for population level control of the COVID19 pandemic , 2020, Journal of Infection.
[5] I. Castellví,et al. Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists. , 2020, European journal of rheumatology.
[6] Theodora Psaltopoulou,et al. Hematological findings and complications of COVID‐19 , 2020, American journal of hematology.
[7] Haibo Xu,et al. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19 , 2020, Journal of Infection.
[8] C. Hung,et al. Prolonged virus shedding even after seroconversion in a patient with COVID-19 , 2020, Journal of Infection.
[9] B. Fernández-Gutiérrez. COVID-19 with Pulmonary Involvement. An Autoimmune Disease of Known Cause. , 2020, Reumatologia clinica.
[10] C. Montecucco,et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies , 2020, Annals of the Rheumatic Diseases.
[11] T. West,et al. Covid-19 in Critically Ill Patients in the Seattle Region — Case Series , 2020, The New England Journal of Medicine.
[12] R. Cron,et al. The Rheumatologist’s Role in COVID-19 , 2020, The Journal of Rheumatology.
[13] D. Galarza-Delgado,et al. Are my patients with rheumatic diseases at higher risk of COVID-19? , 2020, Annals of the Rheumatic Diseases.
[14] F. Ingegnoli,et al. COVID-19 infection and rheumatoid arthritis: Faraway, so close! , 2020, Autoimmunity Reviews.
[15] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[16] Wei Wang,et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.
[17] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[18] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[19] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[20] Michael G. Katze,et al. Into the Eye of the Cytokine Storm , 2012, Microbiology and Molecular Reviews.
[21] Jin-Kui Yang,et al. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes , 2009, Acta Diabetologica.
[22] J. Chan,et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS , 2006, Diabetic medicine : a journal of the British Diabetic Association.